These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 21506642)
21. Virus-like particles: designing an effective AIDS vaccine. Young KR; McBurney SP; Karkhanis LU; Ross TM Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718 [TBL] [Abstract][Full Text] [Related]
22. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Glück R; Moser C; Metcalfe IC Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680 [TBL] [Abstract][Full Text] [Related]
23. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980 [TBL] [Abstract][Full Text] [Related]
24. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436 [TBL] [Abstract][Full Text] [Related]
25. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Kammer AR; Amacker M; Rasi S; Westerfeld N; Gremion C; Neuhaus D; Zurbriggen R Vaccine; 2007 Oct; 25(41):7065-74. PubMed ID: 17766014 [TBL] [Abstract][Full Text] [Related]
26. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665 [TBL] [Abstract][Full Text] [Related]
37. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699 [TBL] [Abstract][Full Text] [Related]
38. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
40. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Ruf BR; Colberg K; Frick M; Preusche A Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]